Drug Trial Radar · NCT02728089
Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)
Last checked: Nov 20, 2026Latest source record: Feb 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
115
Actual
Start
Apr 14, 2016
Primary completion
Sep 5, 2017
Study completion Sep 5, 2017
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multi-site, non-randomized, open-label study evaluating the safety and efficacy of MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) for the treatment of complicated urinary tract infection (cUTI) including pyelonephritis (uncomplicated or complicated pyelonephritis and complicated lower urinary tract infection) in Japanese participants. Efficacy will be primarily assessed by microbiological response defined as eradication of the baseline pathogen or pathogens.
Conditions
- Urinary Tract Infection (UTI)
- Complicated Urinary Tract Infection
- Pyelonephritis
- Uncomplicated Pyelonephritis
Interventions
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)Drug
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Microbiological Response of Eradication at Test of Cure (TOC)Time frame: Day 14 (14 days post first dose of study drug)
- Percentage of Participants Who Report 1 or More Adverse Event (AE)Time frame: Up to 42 days post first dose of study drug
- Percentage of Participants Discontinuing Study Drug Due to an AETime frame: Up to 7 days after the first dose of study drug
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.